Notice: file_put_contents(): Write of 144369 bytes failed with errno=28 No space left on device in /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php on line 36

Warning: http_response_code(): Cannot set response code - headers already sent (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 17

Warning: Cannot modify header information - headers already sent by (output started at /opt/frankenphp/design.onmedianet.com/app/src/Arsae/CacheManager.php:36) in /opt/frankenphp/design.onmedianet.com/app/src/Models/Response.php on line 20
Phosphorothioate nucleic acid - Wikipedia Jump to content

Phosphorothioate nucleic acid

Add links
From Wikipedia, the free encyclopedia

A phosphorothioate nucleic acid is a nucleic acid analogue where the backbone phosphate groups each have one oxygen atom replaced with a sulfur atom, making them thiophosphate groups instead.

Structure and properties

[edit]
Sp and Rp-diastereomeric internucleosidic phosphorothioate linkages.

Oligonucleotide phosphorothioates (OPS) are modified oligonucleotides where one of the oxygen atoms in the phosphate moiety is replaced by sulfur. Only the phosphorothioates having sulfur at a non-bridging position as shown in figure are widely used and are available commercially.

Nucleoside organothiophosphate (PS) analogs of nucleotides give oligonucleotides some beneficial properties. Key beneficial properties that PS backbones give nucleotides are diastereomer identification of each nucleotide and the ability to easily follow reactions involving the phosphorothioate nucleotides, which is useful in oligonucleotide synthesis.[1] PS backbone modifications to oligonucleotides protects them against unwanted degradation by enzymes.[2] Modifying the nucleotide backbone is widely used because it can be achieved with relative ease and accuracy on most nucleotides.[1] Fluorescent modifications on 5' and 3' end of oligonucleotides was reported to evaluate the oligonucleotides structures, dynamics and interactions with respect to environment.[3]

The replacement of the non-bridging oxygen with sulfur creates a new center of chirality at phosphorus. In a simple case of a dinucleotide, this results in the formation of a diastereomeric pair of Sp- and Rp-dinucleoside monophosphorothioates whose structures are shown in Figure. In an n-mer oligonucleotide where all (n – 1) internucleosidic linkages are phosphorothioate linkages, the number of diastereomers m is calculated as m = 2(n – 1).

Mergny and Lacroix determined that the addition of a bulky methyl group had a destabilizing effect on the i-motif formation when they compared phosphorothioate, the natural phosphodiester, methylphosphonate, and peptide linkages and determined that only phosphodiester and phosphorothioate oligodeoxynucleotides were capable of forming stable i-motifs.[4]

Applications

[edit]

Being non-natural analogs of nucleic acids, OPS are substantially more stable towards hydrolysis by nucleases, the class of enzymes that destroy nucleic acids by breaking the bridging P-O bond of the phosphodiester moiety. This property determines the use of OPS as antisense oligonucleotides in in vitro and in vivo applications where the extensive exposure to nucleases is inevitable. Similarly, to improve the stability of siRNA, at least one phosphorothioate linkage is often introduced at the 3'-terminus of both sense and antisense strands.

In chirally pure OPS, all-Sp diastereomers are more stable to enzymatic degradation than their all-Rp analogs.[5] However, the preparation of chirally pure OPS remains a synthetic challenge. In laboratory practice, mixtures of diastereomers of OPS are commonly used.

Antisense pharmaceuticals

[edit]

In the United States, the Food and Drug Administration (FDA) has approved the phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and mipomersen (Kynamro) for human therapeutic use in antisense therapy.[6][7] To prevent degradation of the therapeutic oliogoneucleotides, chemical modification is usually required. The most common chemical modification on the oligonucleotides is adding a phosphorothioate linkage to the backbones.[8] However, the phosphrothioate modification can be proinflammatory. Adverse effects including fever, chills or nausea have been observed after local injection of phosphrothioate modified oligonucleotides.[9]

Gapmers often utilize nucleotides modified with phosphorothioate (PS) groups.[10][11] Miravirsen is an antisense phosphorothioate oligonucleotides that is additionally a locked nucleic acid gapmer.[12][13] Other antisense oligonucleotides using phosphorothioates include afovirsen, aganirsen, alicaforsen, bepirovirsen, custirsen, drisapersen, eplontersen, evazarsen, gataparsen, inotersen, IONIS-GCCRRx, nusinersen, oblimersen, olezarsen, pelacarsen, sefaxersen, tofersen, and volanesorsen.

First-generation anti-miRNA oligonucleotides utilized 2’-O-Methyl RNA nucleotides with phosphorothioate internucleotide linkages positioned at both ends to prevent exonuclease attack. This was also shown to have an effect on target affinity. Using the P-S mutation was shown to decrease the Tm of the oligonucleotide, which leads to a lower target affinity.[14]

Other pharmaceuticals

[edit]

In 2017, a two-dose HBV vaccine for adults, the hepatitis B vaccine Heplisav-B gained U.S. Food and Drug Administration (FDA) approval.[15] It uses recombinant HB surface antigen, similar to previous vaccines, but includes a novel CpG 1018 adjuvant, a 22-mer phosphorothioate-linked oligodeoxynucleotide. It was non-inferior concerning immunogenicity.[16]

Phosphorothioate groups are also used in synthetic CpG oligodeoxynucleotides.[17]

Laboratory applications

[edit]

Other applications include phosphorothioate-based ligase-independent cloning,[18][19] sequence saturation mutagenesis, no-SCAR genome editing, nucleotide analog interference mapping, and incremental truncation for the creation of hybrid enzymes, and antibody-oligonucleotide conjugates.

Synthesis

[edit]

Synthesis of OPS is very similar to that of natural oligonucleotides. The difference is that the oxidation step is replaced by sulfur transfer reaction (sulfurization) and that the capping step is performed after the sulfurization. Of many reported reagents capable of the efficient sulfur transfer, only three are commercially available:

Commercial sulfur transfer agents for oligonucleotide synthesis.
  • 3-(Dimethylaminomethylidene)amino-3H-1,2,4-dithiazole-3-thione, DDTT (3) provides rapid kinetics of sulfurization and high stability in solution.[20][21][22] The reagent is available from several sources.[23][24]
  • 3H-1,2-benzodithiol-3-one 1,1-dioxide (4)[25][26] also known as Beaucage reagent displays a better solubility in acetonitrile and short reaction times. However, the reagent is of limited stability in solution and is less efficient in sulfurizing RNA linkages.[21][22]
  • N,N,N'N'-Tetraethylthiuram disulfide (TETD) is soluble in acetonitrile and is commercially available.[27] However, the sulfurization reaction of an internucleosidic DNA linkage with TETD requires 15 min,[28] which is more than 10 times as slow as that with compounds 3 and 4.

References

[edit]
  1. ^ a b Eckstein F (April 2000). "Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them?". Antisense & Nucleic Acid Drug Development. 10 (2): 117–21. doi:10.1089/oli.1.2000.10.117. PMID 10805163.
  2. ^ Stein CA, Subasinghe C, Shinozuka K, Cohen JS (April 1988). "Physicochemical properties of phosphorothioate oligodeoxynucleotides". Nucleic Acids Research. 16 (8): 3209–21. doi:10.1093/nar/16.8.3209. PMC 336489. PMID 2836790.
  3. ^ Michel BY, Dziuba D, Benhida R, Demchenko AP, Burger A (2020). "Probing of Nucleic Acid Structures, Dynamics, and Interactions With Environment-Sensitive Fluorescent Labels". Frontiers in Chemistry. 8 112. Bibcode:2020FrCh....8..112M. doi:10.3389/fchem.2020.00112. PMC 7059644. PMID 32181238.
  4. ^ Mergny, J. (1998-11-01). "Kinetics and thermodynamics of i-DNA formation: phosphodiester versus modified oligodeoxynucleotides". Nucleic Acids Research. 26 (21): 4797–4803. doi:10.1093/nar/26.21.4797. ISSN 1362-4962. PMC 147917. PMID 9776737.
  5. ^ Lebedev, A. V.; Wickstrom, E. (1996). "The chirality problem in P-substituted oligonucleotides". Perspectives in Drug Discovery and Design. 4 (1): 17–40. doi:10.1007/BF02172106.
  6. ^ "FDA approves fomivirsen for CMV". healio. 1 October 1998. Retrieved 18 September 2020.
  7. ^ "FDA approves orphan drug for inherited cholesterol disorder". Drug Topics. 30 January 2013. Retrieved 18 September 2020.
  8. ^ Kole R, Krainer AR, Altman S (January 2012). "RNA therapeutics: beyond RNA interference and antisense oligonucleotides". Nature Reviews. Drug Discovery. 11 (2): 125–140. doi:10.1038/nrd3625. PMC 4743652. PMID 22262036.
  9. ^ Wahlestedt C (June 2013). "Targeting long non-coding RNA to therapeutically upregulate gene expression". Nature Reviews. Drug Discovery. 12 (6): 433–446. doi:10.1038/nrd4018. PMID 23722346. S2CID 288163.
  10. ^ Roberts, Thomas C.; Langer, Robert; Wood, Matthew J. A. (October 2020). "Advances in oligonucleotide drug delivery". Nature Reviews Drug Discovery. 19 (10): 673–694. doi:10.1038/s41573-020-0075-7. ISSN 1474-1784. PMC 7419031. PMID 32782413. S2CID 221097649.
  11. ^ QIAGEN. (2017). Antisense LNA GapmeRs Handbook: LNA-optimized oligonucleotides for strand-specific knockdown of mRNA and IncRNA. Germantown, MD: Author
  12. ^ Gebert, Luca F. R.; Rebhan, Mario A. E.; Crivelli, Silvia E. M.; Denzler, Rémy; Stoffel, Markus; Hall, Jonathan (2014-01-01). "Miravirsen (SPC3649) can inhibit the biogenesis of miR-122". Nucleic Acids Research. 42 (1): 609–621. doi:10.1093/nar/gkt852. ISSN 0305-1048. PMC 3874169. PMID 24068553.
  13. ^ Bonneau, E.; Neveu, B.; Kostantin, E.; Tsongalis, G.J.; De Guire, V. (2019-06-24). "How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market". EJIFCC. 30 (2): 114–127. ISSN 1650-3414. PMC 6599191. PMID 31263388.
  14. ^ Davis, S.; Lollo, B; Freier, S; Esau, C (28 April 2006). "Improved targeting of miRNA with antisense oligonucleotides". Nucleic Acids Research. 34 (8): 2294–2304. doi:10.1093/nar/gkl183. PMC 1459537. PMID 16690972.
  15. ^ "Heplisav-B". U.S. Food and Drug Administration (FDA). Archived from the original on 22 September 2019. Retrieved 22 September 2019.
  16. ^ Dynavax Technologies Corp. "Heplisav-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] label" (PDF). U.S. Food and Drug Administration (FDA). Archived from the original (PDF) on 25 April 2018. Retrieved 27 November 2018.
  17. ^ Dalpke AH, Zimmermann S, Albrecht I, Heeg K (May 2002). "Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo". Immunology. 106 (1): 102–12. doi:10.1046/j.1365-2567.2002.01410.x. PMC 1782689. PMID 11972638.
  18. ^ Blanusa, Milan; Schenk, Alexander; Sadeghi, Hengameh; Marienhagen, Jan; Schwaneberg, Ulrich (2010-11-15). "Phosphorothioate-based ligase-independent gene cloning (PLICing): An enzyme-free and sequence-independent cloning method". Analytical Biochemistry. 406 (2): 141–146. doi:10.1016/j.ab.2010.07.011. ISSN 0003-2697. PMID 20646988.
  19. ^ Marienhagen, Jan; Dennig, Alexander; Schwaneberg, Ulrich (2012-05-01). "Phosphorothioate-Based DNA Recombination: An Enzyme-Free Method for the Combinatorial Assembly of Multiple DNA Fragments". BioTechniques. 52 (5): 287. doi:10.2144/000113865. ISSN 0736-6205. PMID 26307251.
  20. ^ Guzaev, A. P. (2011). "Reactivity of 3H-1,2,4-dithiazole-3-thiones and 3H-1,2-dithiole-3-thiones as sulfurizing agents for oligonucleotide synthesis". Tetrahedron Lett. 52 (3): 434–437. doi:10.1016/j.tetlet.2010.11.086.
  21. ^ a b "Glen Research Report of Products for RNA and DNA Oligonucelotide Synthesis, Modification and Labelling". Glenresearch.com. 2008-01-17. Retrieved 2009-05-12.
  22. ^ a b "Sulfurizing reagent ii and its use in synthesizing oligonucleotide phosphorothioates" (PDF). Glen Research. 18 (1). 2006. Archived from the original (PDF) on 2008-12-02. Retrieved 2009-08-01.
  23. ^ "AM Chemicals, LLC, a supplier of solid supports and reagents for oligonucleotide and organic synthesis on solid phase". Amchemicals.com. Archived from the original on 2009-02-18. Retrieved 2009-05-12.
  24. ^ "Glen Research Corporation products for DNA and RNA oligo synthesis – Minor Base – 40-4037, Sulfurizing Reagent II". Glenresearch.com. 2008-11-14. Archived from the original on 2011-07-11. Retrieved 2009-05-12.
  25. ^ Iyer, R. P.; Egan, W.; Regan, J. B.; Beaucage, S. L. (1990). "3H-1,2-Benzodithiole-3-one 1,1-dioxide as an improved sulfurizing reagent in the solid-phase synthesis of oligodeoxyribonucleoside phosphorothioates". J. Am. Chem. Soc. 112 (3): 1253–1254. Bibcode:1990JAChS.112.1253I. doi:10.1021/ja00159a059.
  26. ^ Beaucage, S. L. (2001). "3H-1,2-benzodithiol-3-one 1,1-dioxide". E-EROS Encyclopedia of Reagents for Organic Synthesis. doi:10.1002/047084289X.rn00167. ISBN 978-0471936237.
  27. ^ "3400/394/392/391 DNA Synthesizer Reagents". Products.appliedbiosystems.com. Retrieved 2009-05-12.
  28. ^ Vu, H.; Hirschbein, B. L. (1991). "Internucleotide phosphite sulfurization with tetraethylthiuram disulfide. Phosphorothioate oligonucleotide synthesis via phosphoramidite chemistry". Tetrahedron Lett. 32 (26): 3005–3008. doi:10.1016/0040-4039(91)80672-S.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Phosphorothioate_nucleic_acid&oldid=1309652201"